Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Oesophageal cancer and the suspected-cancer pathway

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Complete or rapidly progressive obstruction with inability to swallow saliva, aspiration, an impacted food bolus, haematemesis, severe chest pain after vomiting or instrumentation, and suspected perforation require same-day emergency assessment rather than routine pathway referral. Keep the patient nil by mouth when obstruction or perforation is possible, stabilise airway and circulation, and involve upper-GI surgery, gastroenterology, anaesthesia and radiology according to the presentation. Do not push food or tablets through a suspected malignant stricture.

Overview

Recognise oesophageal cancer promptly, use the current UK suspected-cancer pathway without diluting dysphagia as a red flag, and understand how endoscopy, staging, nutrition and multidisciplinary treatment fit together.

Oesophageal cancer most often presents through progressive dysphagia, weight loss, regurgitation or odynophagia, but iron-deficiency anaemia, aspiration and persistent chest or epigastric discomfort may be the first clue. Adenocarcinoma commonly arises in the distal oesophagus or junction in association with Barrett's oesophagus, reflux, obesity and smoking. Squamous-cell carcinoma can occur throughout the oesophagus and is associated with tobacco, alcohol and other mucosal exposures. Risk factors change probability; they do not replace symptom-led referral.

The suspected-cancer pathway is a route to timely definitive investigation, not a diagnosis. Endoscopy should document tumour level, length, circumference, luminal patency and junctional involvement and obtain adequate tissue. Once malignancy is confirmed, CT assesses distant and local anatomy. PET-CT can disclose occult metastases in potentially curable oesophageal or junctional disease; EUS refines local wall and nodal staging when traversable and when the result will alter management. Staging laparoscopy is selective rather than automatic for oesophageal disease.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Referral for new dysphagia

A 43-year-old man reports six weeks of progressive difficulty swallowing solid food and has begun choosing soups. He has no weight loss and does not smoke. What is the best action?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12: Suspected cancer recognition and referralCurrent symptom and age combinations for oesophageal and stomach suspected-cancer pathways.
  • NICE NG83: Oesophago-gastric cancer assessment and managementNational staging, radical treatment, obstruction, palliative and nutritional recommendations, including the 2023 obstruction update.
  • BSG and AUGIS upper-GI endoscopy quality standardsUK standards for complete mucosal inspection, lesion recognition, reporting and early upper-GI cancer diagnosis.
  • NICE CG32: Nutrition support for adultsAssessment, enteral and parenteral support, monitoring and refeeding-risk safeguards.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Treatment decisions depend on stage, histology, tumour site, performance status, frailty, cardiopulmonary reserve and the patient's priorities. The MDT may offer endoscopic mucosal therapy, oesophagectomy with peri-operative systemic treatment, neoadjuvant or definitive chemoradiotherapy, or symptom-focused care. Dysphagia palliation can involve systemic treatment, radiotherapy, endoscopic stenting or other techniques, but intervention should be selected alongside nutrition and anticipated survival because every option has burdens.

Key points

  • NICE recommends a suspected-cancer pathway referral for dysphagia at any adult age; a trial of acid suppression must not postpone that referral.
  • People aged 55 or over with weight loss plus upper abdominal pain, reflux or dyspepsia also meet the oesophageal or stomach cancer referral threshold.
  • Progression from difficulty with solids to difficulty with liquids suggests mechanical narrowing, although advanced dysmotility and benign strictures remain important differentials.
  • Upper-GI endoscopy defines the lesion and provides histology; biopsy technique and lesion description should support treatment planning rather than merely record a narrowed lumen.
  • Squamous-cell carcinoma and adenocarcinoma differ in distribution, risk pattern and treatment options, so histological subtype and exact relationship to the gastro-oesophageal junction matter.
  • Potentially curative disease is staged through an oesophago-gastric MDT using cross-sectional imaging, PET-CT and selective EUS or laparoscopy according to the clinical question.
  • Malnutrition and sarcopenia are common at diagnosis; swallowing safety and dietetic intervention should begin during staging, not after a final treatment decision.
  • Endoscopic resection can cure carefully staged superficial neoplasia, while more advanced local disease may require surgery, chemotherapy, chemoradiotherapy or a definitive non-operative strategy.

Aetiology

01

Reflux and Barrett pathway

Chronic reflux, Barrett metaplasia, central obesity and smoking increase distal oesophageal adenocarcinoma risk through metaplasia-dysplasia progression.

02

Squamous carcinogen exposure

Smoking and alcohol strongly increase squamous-cell carcinoma risk; cumulative exposure and nutritional or social factors often cluster.

03

Structural and host susceptibility

Increasing age, achalasia, prior caustic injury and selected inherited conditions increase risk, while many cancers arise without a known precursor.

Pathophysiology

  1. 1
    Dysplastic epithelial transformation

    Squamous mucosa or Barrett epithelium accumulates molecular alterations and progresses from dysplasia to invasive carcinoma through basement membrane.

  2. 2
    Circumferential and mural invasion

    Tumour narrows the lumen and penetrates an oesophageal wall lacking a serosal barrier, causing progressive dysphagia and local extension.

  3. 3
    Early lymphatic dissemination

    Longitudinal submucosal lymphatics permit regional nodal spread before a lesion appears bulky, with later liver, lung or other metastasis.

Clinical features and red flags

Progressive dysphagiaRed flag

New food sticking, prolonged mealtimes or avoidance of meat and bread may precede obvious liquid dysphagia. Ask where food seems to stick, but remember that perceived level does not reliably locate the lesion.

Weight and intake change

Unintentional weight loss, early satiety, reduced portions or reliance on liquids suggests both cancer risk and nutritional urgency. Record a measured weight trajectory rather than accepting a vague statement that appetite is poor.

Regurgitation and aspirationRed flag

Nocturnal regurgitation, coughing after swallowing, recurrent chest infection or a wet voice can reflect proximal pooling above an obstruction. Inability to manage saliva is an acute obstruction warning.

Bleeding or anaemia

Haematemesis or melaena requires the acute upper-GI bleeding pathway. More often, chronic occult loss produces iron-deficiency anaemia, fatigue and exertional breathlessness that still require expedited investigation.

Advanced disease clues

Hoarseness, persistent cough, focal bone pain, supraclavicular nodes, hepatomegaly or progressive back pain may indicate local invasion or metastasis and should be communicated on referral and staging requests.

Investigations

  1. 01
    Upper-GI endoscopy with biopsyFirst step
    Why
    Visualise the obstruction, define its extent and obtain diagnostic histology.
    Interpretation and limitations
    Histology distinguishes adenocarcinoma, squamous carcinoma and benign or unusual lesions. A non-diagnostic superficial biopsy does not overrule a malignant appearance; repeat targeted sampling or an alternative tissue route should be agreed urgently.
  2. 02
    Contrast CT chest and abdomen
    Why
    Assess local relationships, nodes, distant spread and treatment feasibility.
    Interpretation and limitations
    CT may reveal invasion, liver or lung metastases and alternative causes of dysphagia. Radiological nodal size is imperfect; the MDT integrates CT with histology and further staging rather than declaring curability from CT alone.
  3. 03
    FDG PET-CT
    Why
    Search for metabolically active occult metastatic disease before radical treatment.
    Interpretation and limitations
    Use in potentially curable oesophageal or gastro-oesophageal junction cancer according to NICE and MDT selection. Inflammatory uptake and small-volume disease can mislead, so unexpected findings may need confirmation.
  4. 04
    Endoscopic ultrasound
    Why
    Refine tumour-wall and regional-node staging when it can change treatment.
    Interpretation and limitations
    EUS is most useful in selected potentially radical cases. A tight non-traversable tumour limits assessment; forcing the scope or routine dilatation solely for staging can create perforation risk.
  5. 05
    Pathology and predictive markers
    Why
    Confirm subtype and provide information needed for current oncology options.
    Interpretation and limitations
    The specialist pathology pathway records site and histology and requests treatment-relevant markers for advanced disease. Required panels evolve, so use the current regional oncology protocol rather than an old fixed list.
  6. 06
    Fitness and nutritional assessment
    Why
    Judge whether proposed radical treatment is tolerable and prevent avoidable depletion.
    Interpretation and limitations
    Review weight loss, swallowing safety, frailty, performance status, cardiopulmonary reserve, FBC, renal and liver profiles. Severe malnutrition can alter timing and route of treatment but should not cause unplanned diagnostic delay.

Differential diagnosis

01

Peptic or eosinophilic stricture

Long reflux history or food impaction with benign biopsies may indicate inflammatory narrowing, but progressive alarm symptoms require adequate repeat sampling.

02

Achalasia

Liquids and solids affected from early on with a smooth taper and diagnostic manometry favours motor failure after pseudoachalasia is excluded.

03

Benign or functional dysphagia

Stable intermittent symptoms without weight loss may reflect rings or gut-brain disease, but dysphagia itself still warrants timely structural assessment.

Additional chapter-specific clues

Benign mimic caution

Reflux stricture, eosinophilic oesophagitis, achalasia and motility disorders can resemble cancer. Their possibility is a reason for high-quality investigation, not for delaying the cancer pathway.

Management

01ReferUse the cancer pathway promptlyFirst stepAn adult reports dysphagia, or a person aged 55 or over has weight loss with upper abdominal pain, reflux or dyspepsia.+
  1. 1Clarify progression, intake, weight, aspiration, bleeding and performance status, examine for metastatic signs, and submit a suspected-cancer referral using the applicable devolved-nation or local route.
  2. 2Safety-net immediate deterioration, particularly inability to swallow saliva, food-bolus obstruction, haematemesis or severe chest pain, because these features require acute assessment rather than waiting for an appointment.
  3. 3Do not substitute empirical PPI treatment, a normal plain radiograph or an old benign endoscopy for current investigation of a new qualifying symptom.
02StageDefine potentially curable diseaseEndoscopic biopsy confirms oesophageal or junctional malignancy without an obvious emergency complication.+
  1. 1Complete protocolled CT and review pathology in the specialist MDT, clarifying the epicentre and whether the lesion should follow an oesophageal, junctional or gastric treatment pathway.
  2. 2Add PET-CT for potentially curative oesophageal or junctional disease and use EUS or selective laparoscopy only when the information is likely to change a radical plan.
  3. 3Assess nutrition, frailty and cardiopulmonary fitness in parallel, then present genuine treatment choices with expected swallowing, recovery, recurrence and quality-of-life consequences.
03SupportRelieve dysphagia proportionatelyOral intake is unsafe or inadequate during staging, radical treatment or non-curative care.+
  1. 1Obtain specialist dietetic and swallowing input, choose texture and supplements safely, and discuss enteral access with the treating MDT because some routes can complicate future surgery.
  2. 2For non-curative obstruction, compare systemic therapy, radiotherapy, stenting and other endoscopic measures by speed of benefit, adverse effects, expected survival and the person's priorities.
  3. 3After any intervention, check pain, reflux, migration, aspiration, intake and re-obstruction, and provide a rapid contact route rather than assuming restored luminal diameter guarantees nutrition.

Complications

01

Obstruction and malnutrition

Progressive luminal narrowing limits solids then liquids, causing dehydration, sarcopenia and aspiration risk before staging and treatment are complete.

02

Airway fistula or aspiration

Local invasion can communicate with tracheobronchial structures, causing cough with swallowing, recurrent pneumonia and severe respiratory compromise.

03

Bleeding and metastatic disease

Tumour ulceration causes anaemia or haematemesis, while nodal and distant spread produces pain, cachexia and loss of curative options.

Monitoring and follow-up

  • Track weight, oral intake, hydration, swallowing safety and functional status from referral through treatment, with early specialist dietetic review.
  • Record completion and results of endoscopy, histology, CT and any indicated PET-CT or EUS so the MDT is not making decisions from an incomplete stage.
  • During radical treatment, monitor regimen-specific haematological, renal, nutritional and cardiopulmonary toxicity through the oncology or surgical protocol.
  • After endoscopic or surgical treatment, use the specialist surveillance plan and investigate new dysphagia rather than assuming it is postoperative scarring.
  • In palliative care, review swallowing, secretion burden, pain, bleeding, aspiration and stent complications while aligning repeated procedures with goals of care.

Special situations

Dysphagia stands alone

Unlike several age-and-symptom combinations in NG12, dysphagia itself is sufficient for suspected oesophageal cancer referral and should not be diluted by a low-risk profile.

Perceived level misleads

Patients may point to the neck even when food is held up distally, so anatomical localisation must come from investigation rather than symptom mapping.

Biopsy is not staging

Histological proof names the disease, while CT, PET-CT and selective local tests determine extent; neither part can substitute for the other.

Nutrition is active treatment

Maintaining intake can improve treatment delivery and recovery, but the access route should be planned with surgeons and oncologists so it does not compromise reconstruction.

A stent has trade-offs

Stents can restore swallowing quickly but may cause pain, reflux, migration or fistulation; slower alternatives may suit some people with a longer expected course.

Common pitfalls

  1. 01

    Trying a PPI for several weeks before referring an adult with new dysphagia.

  2. 02

    Assuming young age, absence of smoking or a normal examination excludes oesophageal cancer.

  3. 03

    Forcing an endoscope or staging probe through a nearly occlusive lesion without a safe interventional plan.

  4. 04

    Completing sequential staging tests while weight loss and aspiration remain unaddressed.

  5. 05

    Treating a non-diagnostic biopsy as reassurance despite an endoscopically malignant stricture.

  6. 06

    Choosing feeding access or a palliative stent before the oesophago-gastric MDT clarifies treatment intent.